Jean-Luc Béjot, M.D., MBA, has over 29 years of international experience in clinical development and in medical affairs in the life science industries. His main experience and expertise lies in early stage (phases I and II) clinical development, and he has been exposed at various depth to many steps of medicinal products life cycle (medicinal chemistry, pre-clinical, clinical, marketing, licensing). He has worked mostly on biotechnology and medicinal products, but also on OTC products, and was involved in a few medical devices. Therapeutic areas have been diverse, with a special emphasis on oncology.
Prior to Voisin Consulting Life Sciences, he was interim Medical Affairs Director in the Endocrinology Specialty Franchise and in the Specialty Franchises Clinical Operations at Ipsen, working on a somatostatin analogue indicated for neuroendocrine tumours and acromegaly. Before Ipsen, he was Director of Clinical Operations at Debiopharm International SA, a Swiss-based drug development company focused on oncology therapeutic area, where he managed the clinical operations team and oversaw the conduct of several phase I/II oncology trials. Prior to Debiopharm, he was free-lance interim medical manager for various biotechnology companies, including the French subsidiary of Genzyme, where he worked on orphan drugs. Before, he was Vice President, Development at OPi, a biopharmaceutical company based near Lyon, France, and specialised in rare and severe diseases. He was responsible for the development strategy of the company’s product portfolio, which included two monoclonal antibodies in rare haematology indications, and for the management of the development team.
Prior to OPi, Jean-Luc Béjot has held various managerial positions at Prestwick Scientific Capital, Inc., in Washington, DC (United States), Novartis Consumer Health in Nyon (Switzerland), Quintiles-BRI, a Washington, DC based contract research organisation, the Beaufour-Ipsen group in Washington, DC and Paris, and Laboratoires Cassenne (former Roussel-Uclaf group).
He has also founded his own biotechnology company, Karcinolys, which is developing an oncolytic virus against rare and severe cancers, currently at preclinical stage.
Jean-Luc Béjot holds an MD from X. Bichat Medical School (Paris VII University) and an MBA (International Executive MBA programme) from Georgetown University (Washington, DC, USA).